AKBA - Akebia Therapeutics Inc Stock Price, Fair Value and News

1.14USD0.00 (0.00%)Delayed as of 17 May 2024, 02:07 pm ET

Market Summary

USD1.140.00

Delayedas of 17 May 2024, 02:07 pm

0.00%

AKBA Alerts

Big fall in Revenue (Y/Y)

Big jump in Earnings (Y/Y)
Losses in recent quarter

AKBA Stock Price

View Fullscreen

AKBA RSI Chart

AKBA Valuation

Market Cap

238.9M

Price/Earnings (Trailing)

-5.55

Price/Sales (Trailing)

1.4

EV/EBITDA

-5.09

Price/Free Cashflow

-9.45

AKBA Price/Sales (Trailing)

AKBA Profitability

Operating Margin

61.45%

EBT Margin

-30.37%

Return on Equity

157.87%

Return on Assets

-19.08%

Free Cashflow Yield

-10.58%

AKBA Fundamentals

AKBA Revenue

Revenue (TTM)

171.0M

Rev. Growth (Yr)

-18.74%

Rev. Growth (Qtr)

-41.98%

AKBA Earnings

Earnings (TTM)

-43.0M

Earnings Growth (Yr)

33.09%

Earnings Growth (Qtr)

-3.0K%

Breaking Down AKBA Revenue

52 Week Range

1.18

(Low)(High)

Last 7 days

-14.3%

Last 30 days

-18.6%

Last 90 days

-21.4%

Trailing 12 Months

0.9%

How does AKBA drawdown profile look like?

AKBA Financial Health

Current Ratio

1.7

Debt/Equity

-1.11

Debt/Cashflow

-0.84

AKBA Investor Care

Shares Dilution (1Y)

12.73%

Diluted EPS (TTM)

-0.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	171.0M	0	0	0
2023	271.1M	0	186.4M	193.9M
2022	221.0M	294.9M	294.8M	292.7M
2021	236.0M	198.7M	232.5M	211.7M
2020	350.8M	340.2M	263.2M	272.1M
2019	234.5M	286.5M	325.3M	335.0M
2018	203.0M	223.3M	235.2M	207.7M
2017	22.5M	51.0M	92.2M	178.0M
2016	0	0	0	1.8M
2015	612.2K	525.2K	410.2K	0
2014	962.4K	875.0K	787.6K	700.2K
2013	0	0	1.5M	1.0M
2012	0	0	0	2.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Akebia Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 29, 2024	butler john p.	sold	-73,580	1.58	-46,570	ceo and president
Feb 29, 2024	dahan michel	sold	-13,684	1.58	-8,661	svp, chief operating officer
Feb 29, 2024	hadas nicole r.	sold	-9,438	1.58	-5,974	svp, chief legal officer
Feb 29, 2024	burke steven keith	sold	-11,327	1.58	-7,169	svp, chief medical officer
Feb 27, 2024	burke steven keith	sold	-12,717	1.52	-8,367	svp, chief medical officer
Feb 27, 2024	hadas nicole r.	sold	-11,264	1.52	-7,411	svp, chief legal officer
Feb 27, 2024	dahan michel	sold	-16,330	1.52	-10,744	svp, chief operating officer
Feb 27, 2024	butler john p.	sold	-57,354	1.52	-37,733	ceo and president
Feb 01, 2024	burke steven keith	sold	-40,842	1.68	-24,311	svp, chief medical officer
Feb 01, 2024	butler john p.	sold	-78,101	1.68	-46,489	ceo and president

Which funds bought or sold AKBA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Tower Research Capital LLC (TRC)	added	1,933	61,291	63,404	-%
May 15, 2024	Point72 Asia (Singapore) Pte. Ltd.	new	-	340,805	340,805	0.09%
May 15, 2024	Squarepoint Ops LLC	added	733	428,146	466,035	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	unchanged	-	35,000	110,000	-%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	550	550	-%
May 15, 2024	Orchard Capital Management, LLC	added	24.92	90,818	198,482	0.06%
May 15, 2024	Schonfeld Strategic Advisors LLC	sold off	-100	-25,482	-	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	reduced	-4.19	85,690	292,707	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	added	170	43,974	58,694	-%
May 15, 2024	MIRABELLA FINANCIAL SERVICES LLP	sold off	-100	-80,972	-	-%

Are Funds Buying or Selling AKBA?

Are funds buying AKBA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AKBA

No. of Funds

Unveiling Akebia Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	4.04%	7,607,472	SC 13G/A
Feb 09, 2024	satter muneer a	8.6%	16,205,119	SC 13G/A
Feb 10, 2023	satter muneer a	8.2%	15,090,119	SC 13G/A
Feb 09, 2023	vanguard group inc	6.11%	11,238,870	SC 13G/A
Jan 20, 2023	state street corp	0.31%	571,936	SC 13G/A
Dec 19, 2022	satter muneer a	7.5%	13,864,330	SC 13G
Jul 08, 2022	blackrock inc.	2.4%	4,340,026	SC 13G
Jun 09, 2022	vanguard group inc	10.00%	18,359,420	SC 13G/A
Feb 10, 2022	state street corp	6.71%	11,743,461	SC 13G/A
Feb 09, 2022	vanguard group inc	7.56%	13,235,669	SC 13G/A

Recent SEC filings of Akebia Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 13, 2024	144	Notice of Insider Sale Intent
May 13, 2024	144	Notice of Insider Sale Intent
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	4	Insider Trading
May 09, 2024	8-K	Current Report
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 25, 2024	ARS	ARS

Peers (Alternatives to Akebia Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Akebia Therapeutics Inc News

Latest updates

Akebia Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-42.0%	32,607,000	56,196,000	42,046,000	40,127,000	55,547,000	48,714,000	126,759,000	61,699,000	57,677,000	48,756,000	52,913,000	52,304,000	78,530,000	15,000,000	90,142,000	88,478,000	69,555,000	91,977,000	100,803,000	72,666,000	59,850,000
Cost Of Revenue	-39.0%	11,605,000	19,018,500	18,009,000	19,484,000	-3,043,000	38,281,000	18,600,000	31,344,000	47,626,500	15,944,000	52,495,000	34,606,000	63,234,000	30,345,000	174,616,000	27,713,000	38,147,000	38,263,000	37,669,000	31,257,000	7,768,000
Operating Expenses	-0.4%	35,938,000	36,072,500	37,073,000	45,581,000	64,199,500	60,838,000	73,690,000	88,848,000	75,389,500	87,698,000	79,759,000	82,634,000	78,868,000	87,738,000	89,345,000	119,890,000	126,299,000	109,619,000	122,657,000	117,378,000	142,240,000
S&GA Expenses	0.0%	25,438,000	25,435,000	22,710,000	25,053,000	29,908,000	31,887,000	32,240,000	44,566,000	44,804,000	46,357,000	41,651,000	41,328,000	40,463,000	40,171,000	35,482,000	37,983,000	44,918,000	34,178,000	36,068,000	34,291,000	55,121,000
R&D Expenses	-1.4%	9,731,000	9,865,500	13,330,000	19,686,000	32,098,000	28,028,000	26,027,000	43,833,000	29,556,000	40,471,000	37,214,000	40,611,000	37,578,000	46,857,000	52,819,000	81,231,000	80,412,000	74,512,000	85,694,000	82,351,000	87,052,000
EBITDA Margin	-13.4%	-0.26	-0.23	-0.46	-0.32	-0.29	-0.92	-0.92	-1.22	-1.28	-1.61	-1.89	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,752,000	-1,277,000	-845,000	-2,757,000	-28,338,000
Earnings Before Taxes	-Infinity%	-17,985,000	-	-	-26,876,000	-	-	-	-	-	-	-	-	-88,384,000	-59,959,000	-175,751,000	-60,747,000	-96,235,000	-55,862,000	-59,015,000	-75,178,000	-88,392,000
EBT Margin	-13.4%	-0.30	-0.27	-0.51	-0.35	-0.32	-0.96	-0.96	-1.28	-1.33	-1.66	-1.94	-	-	-	-	-	-	-	-	-	-
Net Income	-3029.2%	-17,985,000	614,000	-14,489,000	-26,878,000	-6,070,500	-54,096,000	29,449,000	-63,509,000	-69,862,000	-59,544,000	-83,038,000	-69,580,000	-87,000,000	-59,959,000	-175,751,000	-60,747,000	-94,483,000	-54,585,000	-58,170,000	-72,421,000	-60,054,000
Net Income Margin	6.0%	-0.25	-0.27	-0.31	-0.21	-0.32	-0.54	-0.55	-1.25	-1.33	-1.29	-1.51	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-741.9%	-19,432,000	-2,308,000	-7,167,000	-17,540,000	-54,679,000	33,805,000	-30,660,000	-21,734,000	-62,808,000	-56,270,000	-63,141,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-6.7%	225	242	235	254	281	356	444	530	542	529	602	612	629	644	676	745	788	771	795	824	891
Current Assets	-4.4%	113	118	110	118	121	185	242	308	305	271	330	331	365	371	391	449	341	310	299	316	347
Cash Equivalents	1.6%	44.00	43.00	47.00	54.00	57.00	90.00	148	147	178	152	209	249	255	229	172	248	118	150	123	87.00	63.00
Inventory	62.7%	26.00	16.00	18.00	21.00	20.00	22.00	45.00	40.00	41.00	37.00	34.00	38.00	45.00	61.00	88.00	105	112	116	116	122	115
Net PPE	-10.0%	3.00	4.00	4.00	4.00	5.00	5.00	6.00	6.00	6.00	7.00	7.00	8.00	8.00	9.00	9.00	9.00	10.00	10.00	13.00	11.00	10.00
Goodwill	0%	59.00	59.00	59.00	59.00	59.00	59.00	59.00	59.00	59.00	59.00	55.00	55.00	55.00	55.00	55.00	55.00	55.00	55.00	55.00	55.00	55.00
Liabilities	-7.2%	253	272	274	281	300	351	436	471	519	455	465	437	415	397	358	375	391	376	328	304	324
Current Liabilities	-33.4%	66.00	100	80.00	92.00	88.00	130	193	237	258	261	189	166	173	187	181	196	214	208	223	186	203
Long Term Debt	75.4%	30.00	17.00	35.00	18.00	26.00	34.00	-	-	-	-	97.00	97.00	97.00	96.00	77.00	76.00	76.00	76.00	-	-	-
LT Debt, Current	-100.0%	-	18.00	8.00	24.00	24.00	32.00	66.00	98.00	98.00	98.00	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	17.00	35.00	18.00	26.00	34.00	-	-	-	-	97.00	97.00	97.00	96.00	77.00	76.00	76.00	76.00	-	-	-
Shareholder's Equity	10.9%	-27.26	-30.58	-	-	-19.12	5.00	8.00	59.00	23.00	74.00	137	175	214	244	318	370	396	393	468	519	566
Retained Earnings	-1.1%	-1,626	-1,608	-1,609	-1,595	-1,583	-1,557	-1,550	-1,496	-1,526	-1,462	-1,389	-1,330	-1,247	-1,177	-1,090	-1,030	-854	-794	-699	-644	-586
Additional Paid-In Capital	1.4%	1,600	1,578	1,570	1,568	1,565	1,562	1,559	1,556	1,549	1,537	1,527	1,505	1,461	1,425	1,408	1,401	1,251	1,189	1,167	1,164	1,153
Shares Outstanding	7.6%	209	195	188	188	186	184	184	182	180	177	163	161	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	170	-	-	-	64.00	-	-	-	632	-	-	-	1,914	-	-	-	566	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-741.9%	-19,432	-2,308	-7,167	3,631	-17,540	-54,679	33,805	-30,660	-21,620	-62,808	-56,270	-63,141	-70,746	-30,782	-27,237	37,220	-89,589	-92,135	10,989	-38,366	-137,929
Share Based Compensation	55.2%	2,360	1,521	1,800	3,500	2,489	3,050	3,355	6,900	4,536	4,636	5,593	6,514	5,992	6,088	6,592	6,864	4,916	4,934	2,613	2,284	2,094
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-114	-	-	20,000	19,941	59,683	-49,937	-49,995	245	22,280	24,390	54,033	110,473
Cashflow From Financing	1532.2%	18,475	-1,290	50.00	-8,000	-15,966	-1.00	-32,937	-9.00	47,545	5,403	16,482	37,369	74,477	30,511	1,054	142,807	57,348	94,418	195	8,804	-14,447
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	426	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AKBA Income Statement

2024-03-31

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues
Total revenues	$ 32,607	$ 40,005
Cost of goods sold
Cost of product and other revenue	2,594	11,178
Amortization of intangible asset	9,011	9,011
Total cost of goods sold	11,605	20,189
Operating expenses:
Research and development	9,731	19,686
Selling, general and administrative	25,438	25,053
License	711	568
Restructuring	58	106
Total operating expenses	35,938	45,413
Loss from operations	(14,936)	(25,597)
Other income (expense)
Interest expense	(2,498)	(1,561)
Other income	95	282
Change in fair value of warrant liability	(129)	0
Loss on extinguishment of debt	(517)	0
Net loss before income taxes	(17,985)	(26,876)
Net (loss) income, basic	(17,985)	(26,876)
Net (loss) income, diluted	(17,985)	(26,876)
Comprehensive loss	$ (17,985)	$ (26,876)
Net loss per share:
Basic (in dollars per share)	$ (0.09)	$ (0.15)
Diluted (in dollars per share)	$ (0.09)	$ (0.15)
Weighted average common shares outstanding:
Basic (in shares)	204,955,151	184,768,983
Diluted (in shares)	204,955,151	184,768,983
Product revenue, net
Revenues
Total revenues	$ 31,009	$ 34,706
License, collaboration and other revenue
Revenues
Total revenues	$ 1,598	$ 5,299

AKBA Balance Sheet

2024-03-31

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 41,961	$ 42,925
Inventories	25,532	15,691
Accounts receivable, net	26,620	39,290
Prepaid expenses and other current assets	18,831	20,243
Total current assets	112,944	118,149
Property and equipment, net	3,265	3,629
Operating right-of-use assets	11,399	12,416
Intangible asset, net	27,032	36,042
Goodwill	59,044	59,044
Other long-term assets	11,793	12,423
Total assets	225,477	241,703
Current liabilities:
Accounts payable	11,882	14,635
Accrued expenses and other current liabilities	53,910	67,735
Short-term deferred revenue	695	0
Current portion of long-term debt	0	17,500
Total current liabilities	66,487	99,870
Deferred revenue, net of current portion	43,296	43,296
Long-term operating lease liabilities	7,636	8,947
Long-term debt, net	30,145	17,183
Liability related to sale of future royalties	53,498	54,013
Refund liability to customer	39,927	40,093
Warrant liability	4,975	0
Other long-term liabilities	6,771	8,885
Total liabilities	252,735	272,287
Commitments and contingencies (Note 10)
Stockholders' deficit:
Preferred stock $0.00001 par value, 25,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock $0.00001 par value; 350,000,000 shares authorized at March 31, 2024 and December 31, 2023; 209,454,149 and 194,582,539 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	2	2
Additional paid-in capital	1,599,669	1,578,358
Accumulated other comprehensive income	6	6
Accumulated deficit	(1,626,935)	(1,608,950)
Total stockholders' deficit	(27,258)	(30,584)
Total liabilities and stockholders' deficit	$ 225,477	$ 241,703

About Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. John P. Butler MBA
WEBSITE	akebia.com
INDUSTRY	Biotechnology
EMPLOYEES	204

Akebia Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Akebia Therapeutics Inc? What does AKBA stand for in stocks?

AKBA is the stock ticker symbol of Akebia Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Akebia Therapeutics Inc (AKBA)?

As of Thu May 16 2024, market cap of Akebia Therapeutics Inc is 238.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AKBA stock?

You can check AKBA's fair value in chart for subscribers.

What is the fair value of AKBA stock?

You can check AKBA's fair value in chart for subscribers. The fair value of Akebia Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Akebia Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AKBA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Akebia Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AKBA is over valued or under valued. Whether Akebia Therapeutics Inc is cheap or expensive depends on the assumptions which impact Akebia Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AKBA.

What is Akebia Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, AKBA's PE ratio (Price to Earnings) is -5.55 and Price to Sales (PS) ratio is 1.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AKBA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Akebia Therapeutics Inc's stock?

In the past 10 years, Akebia Therapeutics Inc has provided -0.253 (multiply by 100 for percentage) rate of return.